Profile
Paul Rivard is currently the VP-Operations & General Counsel at MyMD Pharmaceuticals (Florida), Inc. Previously, he held the position of President & General Counsel at MIRA Pharmaceuticals, Inc. He also served as the Chief Legal Officer & Vice President-Operations at TNF Pharmaceuticals, Inc. from 2021 to 2023.
Mr. Rivard completed his undergraduate degree at Clarkson University in 1992 and obtained his graduate degree from Columbus School of Law in 1998.
Paul Rivard active positions
| Companies | Position | Start |
|---|---|---|
MyMD Pharmaceuticals (Florida), Inc.
MyMD Pharmaceuticals (Florida), Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage pharmaceutical company that develops therapeutic platforms | Chief Operating Officer | - |
Former positions of Paul Rivard
| Companies | Position | End |
|---|---|---|
| Q/C TECHNOLOGIES, INC. | Chief Operating Officer | 2023-11-13 |
| MIRA PHARMACEUTICALS, INC. | President | - |
Training of Paul Rivard
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
Clarkson University
Clarkson University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Columbus School of Law
Columbus School of Law Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
MyMD Pharmaceuticals (Florida), Inc.
MyMD Pharmaceuticals (Florida), Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage pharmaceutical company that develops therapeutic platforms | Health Technology |
MyMD Pharmaceuticals, Inc.
MyMD Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage pharmaceutical company that engages in the development of drug products to extend healthy lifespan | Health Technology |
MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. Pharmaceuticals: OtherHealth Technology Develops and sells new molecular synthetic THC for the treatment of adult patients with anxiety and cognitive decline | Health Technology |
- Stock Market
- Insiders
- Paul Rivard
















